Basal insulin glargine vs prandial insulin lispro in type 2 diabetes -: Reply

被引：0
|
作者：
Linn, Thomas [1 ]
Landgraf, W. [2 ]
Bretzel, Reinhard G. [1 ]
机构：
[1] Univ Giessen, Med Klin & Poliklin 3, D-35392 Giessen, Germany
[2] Sanofi Aventis Deutschland GmbH, Med Affairs, Berlin, Germany
来源：
LANCET | 2008年 / 372卷 / 9636期
关键词：
D O I：
10.1016/S0140-6736(08)61154-X
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：372 / 372
页数：1
相关论文
共 50 条
  • [1] Basal insulin glargine vs prandial insulin lispro in type 2 diabetes
    Arnolds, Sabine
    Rave, Klaus
    LANCET, 2008, 372 (9636): : 370 - 371
  • [2] Prandial insulin substitution with insulin lispro or insulin lispro, mid mixture vs. basal therapy with insulin glargine:: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy
    Kazda, C
    Hülstrunk, H
    Helsberg, K
    Langer, F
    Forst, T
    Hanefeld, M
    JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2006, 20 (03) : 145 - 152
  • [3] Equivalence of basal insulin glargine vs prandial insulin lispro for glucose control in type 2 diabetes patients on oral agents - Results of the APOLLO study
    Bretzel, Reinhard G.
    Linn, Thomas
    DIABETES, 2006, 55 : A76 - A76
  • [4] Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (Lispro/ILPS) vs basal/bolus (Glargine/Lispro) therapy
    Ahmann, A. J.
    Rosenstock, J.
    Colon, G.
    Scism-Bacon, J.
    Jiang, H. H.
    Martin, S.
    DIABETOLOGIA, 2007, 50 : S410 - S410
  • [5] Insulin lispro mix 25/75 twice daily (LM25) vs basal insulin glargine once daily and prandial insulin lispro once daily (BP) in type 2 diabetes: insulin intensification
    Tinahones, F. J.
    Gross, J. L.
    Onaca, A.
    Zhou, Z.
    Cleall, S.
    Rodriguez, A.
    DIABETOLOGIA, 2013, 56 : S412 - S412
  • [6] Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents - Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
    Rosenstock, Julio
    Scism-Bacon, Jamie
    Ahmann, Andrew J.
    Jiang, Honghua
    Colon, Gildred
    Martin, Sherry
    DIABETES CARE, 2008, 31 (01) : 20 - 25
  • [7] A comparison of prandial premixed (ILPS/lispro) vs basal bolus (glargine/lispro) insulin therapy in obese patients with type 2 diabetes (T2D)
    Ahmann, Andrew
    Jiang, Honghua
    Martin, Sherry A.
    DIABETES, 2008, 57 : A564 - A564
  • [8] A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1
    Garg, S.
    Dreyer, M.
    Jinnouchi, H.
    Mou, J.
    Qu, Y.
    Hartman, M. L.
    Rosilio, M.
    Jacober, S. J.
    Bastyr, E. J., III
    DIABETES OBESITY & METABOLISM, 2016, 18 : 25 - 33
  • [9] Equivalence of basal insulin glargine versus prandial insulin lispro for glucose control in type 2 diabetes patients on oral agents - results of the APOLLO study
    Bretzel, R. G.
    Nuber, U.
    El-Haschimi, K.
    Linn, T.
    DIABETOLOGIA, 2006, 49 : 93 - 93
  • [10] Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial
    Arturo Rojas
    Georgina Sposetti
    Jorge L. Gross
    Douglas Eugenio Barbieri
    Ran Duan
    Bruno Linetzky
    Janaina Martins De Lana
    Oded Stempa
    Angel Rodriguez
    Diabetology & Metabolic Syndrome, 8
12345